Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price traded up 14.5% during trading on Thursday . The company traded as high as C$1.26 and last traded at C$1.26. 243,945 shares were traded during mid-day trading, an increase of 230% from the average session volume of 73,919 shares. The stock had previously closed at C$1.10.
Analyst Ratings Changes
Separately, Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a report on Thursday, November 14th.
Get Our Latest Stock Report on ONC
Oncolytics Biotech Stock Performance
The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The stock has a fifty day moving average price of C$1.46 and a 200-day moving average price of C$1.40. The firm has a market cap of C$100.69 million, a price-to-earnings ratio of -3.45 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Recommended Stories
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
